PL2931878T3 - Terapeutyczne szczepionki przeciwnowotworowe pochodzące z nowych dendrytycznych linii komórkowych - Google Patents

Terapeutyczne szczepionki przeciwnowotworowe pochodzące z nowych dendrytycznych linii komórkowych

Info

Publication number
PL2931878T3
PL2931878T3 PL13815701T PL13815701T PL2931878T3 PL 2931878 T3 PL2931878 T3 PL 2931878T3 PL 13815701 T PL13815701 T PL 13815701T PL 13815701 T PL13815701 T PL 13815701T PL 2931878 T3 PL2931878 T3 PL 2931878T3
Authority
PL
Poland
Prior art keywords
cell line
dendritic cell
cancer vaccines
therapeutic cancer
vaccines derived
Prior art date
Application number
PL13815701T
Other languages
English (en)
Inventor
Van Sandra Wetering
Adriana Marie Kruisbeek
Original Assignee
Dcprime B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcprime B.V. filed Critical Dcprime B.V.
Publication of PL2931878T3 publication Critical patent/PL2931878T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13815701T 2012-12-11 2013-12-10 Terapeutyczne szczepionki przeciwnowotworowe pochodzące z nowych dendrytycznych linii komórkowych PL2931878T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120196496 EP2743344A1 (en) 2012-12-11 2012-12-11 Therapeutic cancer vaccines derived from a novel dendritic cell line
EP13815701.1A EP2931878B1 (en) 2012-12-11 2013-12-10 Therapeutic cancer vaccines derived from a novel dendritic cell line

Publications (1)

Publication Number Publication Date
PL2931878T3 true PL2931878T3 (pl) 2017-05-31

Family

ID=47355861

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13815701T PL2931878T3 (pl) 2012-12-11 2013-12-10 Terapeutyczne szczepionki przeciwnowotworowe pochodzące z nowych dendrytycznych linii komórkowych

Country Status (7)

Country Link
US (3) US10064923B2 (pl)
EP (2) EP2743344A1 (pl)
CA (1) CA2892518C (pl)
DK (1) DK2931878T3 (pl)
ES (1) ES2613132T3 (pl)
PL (1) PL2931878T3 (pl)
WO (1) WO2014090795A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
EP3703734A1 (en) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
EP3823668A1 (en) 2018-07-16 2021-05-26 DCPrime B.V. A combination product for use in tumor vaccination
JP2022530044A (ja) 2019-04-25 2022-06-27 ディーシープライム・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種方法
EP4127139A1 (en) 2020-03-27 2023-02-08 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021191871A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
AU2021375493A1 (en) 2020-11-05 2023-06-29 Mendus B.V. Use of tumor-independent antigens in immunotherapies
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
JP2024510989A (ja) * 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ ワクチン接種方法及びｃｄ４７遮断薬の使用
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception
WO2023170633A1 (en) 2022-03-10 2023-09-14 Mendus B.V. Use of modified cells of leukemic origin and pd-l1 antibody for enhancing the efficacy of cancer cell therapy
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
US20240173408A1 (en) 2022-11-02 2024-05-30 Mendus B.V. Prognostic biomarkers for cancer relapse vaccination and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139428A1 (de) * 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
AU2002951082A0 (en) * 2002-08-30 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic cellular agents
GB201018014D0 (en) 2010-10-26 2010-12-08 Senzagen Ab Analytical methods and arrays for use in the same
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line

Also Published As

Publication number Publication date
US20190000945A1 (en) 2019-01-03
US11027001B2 (en) 2021-06-08
US20150297698A1 (en) 2015-10-22
ES2613132T3 (es) 2017-05-22
DK2931878T3 (en) 2017-02-13
EP2931878A1 (en) 2015-10-21
EP2743344A1 (en) 2014-06-18
EP2931878B1 (en) 2016-11-02
US10064923B2 (en) 2018-09-04
WO2014090795A1 (en) 2014-06-19
CA2892518C (en) 2023-03-14
US20210346479A1 (en) 2021-11-11
CA2892518A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
PL2931878T3 (pl) Terapeutyczne szczepionki przeciwnowotworowe pochodzące z nowych dendrytycznych linii komórkowych
IL268629B (en) Hiv immunogens for use in anti-vaccination
HK1207967A1 (en) Vaccine
EP2876161A4 (en) VACCINE
SG11201500396TA (en) Tumor vaccination
GB201223386D0 (en) Vaccine
IL231043A (en) vaccine
SG11201403957WA (en) Kit for producing a vaccine
HK1207152A1 (en) Multivalent breast cancer vaccine
GB201119999D0 (en) Vaccine
HK1203817A1 (en) Autologous cancer cell vaccine
GB201003293D0 (en) Cancer vaccine
ZA201402071B (en) Vaccine therapy
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
EP2763699A4 (en) VACCINE
HK1202070A1 (en) Vaccine for tumor immunotherapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
GB201219420D0 (en) Staphyloccal immunogens
GB201120000D0 (en) Vaccine
GB201202090D0 (en) Vaccine
PT2802348T (pt) Kit para a preparação de um agente de vacinação
GB201107549D0 (en) Cancer vaccine
GB201217321D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201206169D0 (en) Vaccine